Novo Nordisk's semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting Competition in the mainland Chinese market for diabetes and weight loss drugs is set to ...

Several companies are in the spotlight. Indigo's damp-leased aircraft extension aids operations. Tata Motors' sales declined, ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

Ozempic may affect your face, bowel movements and hair. Check out the Ozempic side effects before taking this anti-diabetes ...

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies ...